Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights.

Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV.

Molecules. 2020 Jan 15;25(2). pii: E358. doi: 10.3390/molecules25020358. Review.

2.

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.

Zoi I, Karamouzis MV, Xingi E, Sarantis P, Thomaidou D, Lembessis P, Theocharis S, Papavassiliou AG.

Breast Cancer Res. 2019 Dec 3;21(1):132. doi: 10.1186/s13058-019-1226-9.

3.

Autophagy-related Proteins as a Prognostic Factor of Patients With Colorectal Cancer.

Koustas E, Sarantis P, Theoharis S, Saetta AA, Chatziandreou I, Kyriakopoulou G, Giannopoulou I, Michelli M, Schizas D, Papavassiliou AG, Karamouzis MV.

Am J Clin Oncol. 2019 Oct;42(10):767-776. doi: 10.1097/COC.0000000000000592.

4.

The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer-Ways of Enhancing Immunotherapy Action.

Koustas E, Sarantis P, Kyriakopoulou G, Papavassiliou AG, Karamouzis MV.

Cancers (Basel). 2019 Apr 14;11(4). pii: E533. doi: 10.3390/cancers11040533. Review.

5.

Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.

Anestis A, Sarantis P, Theocharis S, Zoi I, Tryfonopoulos D, Korogiannos A, Koumarianou A, Xingi E, Thomaidou D, Kontos M, Papavassiliou AG, Karamouzis MV.

J Cancer Res Clin Oncol. 2019 May;145(5):1221-1233. doi: 10.1007/s00432-019-02872-9. Epub 2019 Feb 25.

PMID:
30805773
6.

Upgraded role of autophagy in colorectal carcinomas.

Koustas E, Sarantis P, Papavassiliou AG, Karamouzis MV.

World J Gastrointest Oncol. 2018 Nov 15;10(11):367-369. doi: 10.4251/wjgo.v10.i11.367.

7.

The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status.

Koustas E, Papavassiliou AG, Karamouzis MV.

PLoS One. 2018 Nov 14;13(11):e0207227. doi: 10.1371/journal.pone.0207227. eCollection 2018.

8.

Physical activity and sociodemographic variables related to global health, quality of life, and psychological factors in breast cancer survivors.

Patsou ED, Alexias GT, Anagnostopoulos FG, Karamouzis MV.

Psychol Res Behav Manag. 2018 Sep 6;11:371-381. doi: 10.2147/PRBM.S170027. eCollection 2018.

9.

Current advances of targeting HGF/c-Met pathway in gastric cancer.

Anestis A, Zoi I, Karamouzis MV.

Ann Transl Med. 2018 Jun;6(12):247. doi: 10.21037/atm.2018.04.42. Review.

10.

Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.

Karamouzis MV, Papavassiliou AG.

Expert Opin Investig Drugs. 2018 Jul;27(7):569-572. doi: 10.1080/13543784.2018.1494724. Epub 2018 Jul 6.

PMID:
29958097
11.

Response: Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials.

Patsou ED, Karamouzis MV.

ESMO Open. 2018 Apr 9;3(3):e000333. doi: 10.1136/esmoopen-2018-000333. eCollection 2018. No abstract available.

12.

Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.

Mihailidou C, Papakotoulas P, Papavassiliou AG, Karamouzis MV.

Oncotarget. 2017 Dec 8;9(12):10360-10374. doi: 10.18632/oncotarget.23164. eCollection 2018 Feb 13.

13.

Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials.

Patsou ED, Alexias GD, Anagnostopoulos FG, Karamouzis MV.

ESMO Open. 2017 Dec 11;2(5):e000271. doi: 10.1136/esmoopen-2017-000271. eCollection 2017.

14.

Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.

Mihailidou C, Karamouzis MV, Schizas D, Papavassiliou AG.

Biochimie. 2017 Nov;142:135-143. doi: 10.1016/j.biochi.2017.09.001. Epub 2017 Sep 7. Review.

PMID:
28890386
15.

Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer.

Koustas E, Karamouzis MV, Mihailidou C, Schizas D, Papavassiliou AG.

Cancer Lett. 2017 Jun 28;396:94-102. doi: 10.1016/j.canlet.2017.03.023. Epub 2017 Mar 18. Review.

PMID:
28323034
16.

RANKL Signaling and ErbB Receptors in Breast Carcinogenesis.

Zoi I, Karamouzis MV, Adamopoulos C, Papavassiliou AG.

Trends Mol Med. 2016 Oct;22(10):839-850. doi: 10.1016/j.molmed.2016.07.009. Epub 2016 Aug 23. Review.

PMID:
27567286
17.

Targeting Androgen/Estrogen Receptors Crosstalk in Cancer.

Karamouzis MV, Papavassiliou KA, Adamopoulos C, Papavassiliou AG.

Trends Cancer. 2016 Jan;2(1):35-48. doi: 10.1016/j.trecan.2015.12.001. Epub 2015 Dec 31. Review.

PMID:
28741499
18.

HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.

Karamouzis MV, Dalagiorgou G, Georgopoulou U, Nonni A, Kontos M, Papavassiliou AG.

Oncotarget. 2016 Feb 2;7(5):5576-97. doi: 10.18632/oncotarget.6762.

19.

The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Engström W, Darbre P, Eriksson S, Gulliver L, Hultman T, Karamouzis MV, Klaunig JE, Mehta R, Moorwood K, Sanderson T, Sone H, Vadgama P, Wagemaker G, Ward A, Singh N, Al-Mulla F, Al-Temaimi R, Amedei A, Colacci AM, Vaccari M, Mondello C, Scovassi AI, Raju J, Hamid RA, Memeo L, Forte S, Roy R, Woodrick J, Salem HK, Ryan EP, Brown DG, Bisson WH.

Carcinogenesis. 2015 Jun;36 Suppl 1:S38-60. doi: 10.1093/carcin/bgv030. Review.

20.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z.

Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review. Erratum in: Carcinogenesis. 2016 Mar;37(3):344.

21.

Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?

Anestis A, Karamouzis MV, Dalagiorgou G, Papavassiliou AG.

Cancer Treat Rev. 2015 Jun;41(6):547-53. doi: 10.1016/j.ctrv.2015.04.009. Epub 2015 Apr 29. Review.

PMID:
25944485
22.

Protein trafficking in colorectal carcinogenesis-targeting and bypassing resistance to currently applied treatments.

Gargalionis AN, Karamouzis MV, Adamopoulos C, Papavassiliou AG.

Carcinogenesis. 2015 Jun;36(6):607-15. doi: 10.1093/carcin/bgv052. Epub 2015 Apr 11. Review.

PMID:
25863128
23.

Machine learning applications in cancer prognosis and prediction.

Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI.

Comput Struct Biotechnol J. 2014 Nov 15;13:8-17. doi: 10.1016/j.csbj.2014.11.005. eCollection 2015. Review.

24.

Sequence patterns mediating functions of disordered proteins.

Exarchos KP, Kourou K, Exarchos TP, Papaloukas C, Karamouzis MV, Fotiadis DI.

Adv Exp Med Biol. 2015;820:49-59. doi: 10.1007/978-3-319-09012-2_3.

PMID:
25417015
25.

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.

Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V.

Lung Cancer. 2014 Jul;85(1):74-80. doi: 10.1016/j.lungcan.2014.03.010. Epub 2014 Mar 16.

PMID:
24746176
26.

The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer.

Sgourakis G, Papapanagiotou A, Kontovounisios C, Karamouzis MV, Dedemadi G, Goumas C, Karaliotas C, Papavassiliou AG.

Tumour Biol. 2014 Jun;35(6):5993-6002. doi: 10.1007/s13277-014-1794-3. Epub 2014 Mar 14.

PMID:
24627130
28.

The value of plasma neurotensin and cytokine measurement for the detection of bowel ischaemia in clinically doubtful cases: a prospective study.

Sgourakis G, Papapanagiotou A, Kontovounisios C, Karamouzis MV, Lanitis S, Konstantinou C, Karaliotas C, Papavassiliou AG.

Exp Biol Med (Maywood). 2013 Aug 1;238(8):874-80. doi: 10.1177/1535370213494663. Epub 2013 Jul 4.

PMID:
23828592
29.

The molecular rationale of Src inhibition in colorectal carcinomas.

Gargalionis AN, Karamouzis MV, Papavassiliou AG.

Int J Cancer. 2014 May 1;134(9):2019-29. doi: 10.1002/ijc.28299. Epub 2013 Jun 21. Review.

30.

What do European community oncologists expect from the European Society for Medical Oncology? Results from a survey among community oncologists in Germany, Greece, Hungary, Italy, Luxembourg, Romania, and Spain.

Eckert R, Curca R, D'Addario G, Lanzetta G, Martorell PM, Mauri D, Rauh S, Schmitz S, Tamas K, Karamouzis MV.

Ann Oncol. 2013 May;24(5):1419-20. doi: 10.1093/annonc/mdt101. Epub 2013 Mar 15. No abstract available.

31.

Targeting insulin-like growth factor in breast cancer therapeutics.

Karamouzis MV, Papavassiliou AG.

Crit Rev Oncol Hematol. 2012 Oct;84(1):8-17. doi: 10.1016/j.critrevonc.2012.02.010. Epub 2012 Mar 15. Review.

PMID:
22424863
32.

Transcription factor networks as targets for therapeutic intervention of cancer: the breast cancer paradigm.

Karamouzis MV, Papavassiliou AG.

Mol Med. 2011;17(11-12):1133-6. doi: 10.2119/molmed.2011.00315. Epub 2011 Sep 6. Review.

33.

Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.

Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE.

Ann Oncol. 2011 Nov;22(11):2482-8. doi: 10.1093/annonc/mdr002. Epub 2011 Mar 1.

34.

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, Savvides P, Romkes M.

J Clin Oncol. 2011 Mar 20;29(9):1140-5. doi: 10.1200/JCO.2010.33.3591. Epub 2011 Feb 22.

35.

Empowering induction therapy for locally advanced head and neck cancer.

Argiris A, Karamouzis MV.

Ann Oncol. 2011 Apr;22(4):773-81. doi: 10.1093/annonc/mdq426. Epub 2010 Sep 23. Review.

36.

DNA repair pathways and their implication in cancer treatment.

Pallis AG, Karamouzis MV.

Cancer Metastasis Rev. 2010 Dec;29(4):677-85. doi: 10.1007/s10555-010-9258-8. Review.

PMID:
20821251
37.

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.

Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA.

Cancer Immunol Immunother. 2010 Dec;59(12):1781-9. doi: 10.1007/s00262-010-0904-3. Epub 2010 Aug 12.

PMID:
20703455
38.

Why is p53-inducible gene 3 rarely affected in cancer?

Kotsinas A, Pateras IS, Galanos PS, Karamouzis MV, Sfikakis PP, Gorgoulis VG.

Oncogene. 2010 Sep 16;29(37):5220. doi: 10.1038/onc.2010.263. Epub 2010 Jul 5. No abstract available.

PMID:
20603616
39.

Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.

Zachos I, Konstantinopoulos PA, Tzortzis V, Gravas S, Karatzas A, Karamouzis MV, Melekos M, Papavassiliou AG.

Expert Opin Investig Drugs. 2010 Jul;19(7):875-87. doi: 10.1517/13543784.2010.496450. Review.

PMID:
20528482
40.

Molecular networks in respiratory epithelium carcinomas.

Pallis AG, Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG.

Cancer Lett. 2010 Sep 1;295(1):1-6. doi: 10.1016/j.canlet.2010.03.014. Epub 2010 Apr 9. Review.

PMID:
20381956
41.

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.

Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG.

Lancet Oncol. 2009 Jul;10(7):709-17. doi: 10.1016/S1470-2045(09)70137-8. Review.

PMID:
19573800
42.

The use of endostatin in the treatment of solid tumors.

Karamouzis MV, Moschos SJ.

Expert Opin Biol Ther. 2009 May;9(5):641-8. doi: 10.1517/14712590902882118 . Review.

PMID:
19368526
43.

Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy.

Zachos I, Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Papatsoris AG, Podimatas T, Papachristodoulou A, Chrisofos M, Deliveliotis C, Papavassiliou AG.

J Cancer Res Clin Oncol. 2009 Sep;135(9):1169-75. doi: 10.1007/s00432-009-0557-9. Epub 2009 Feb 12.

PMID:
19214569
44.

Leiomyosarcoma of the prostate: case report and review of 54 previously published cases.

Vandoros GP, Manolidis T, Karamouzis MV, Gkermpesi M, Lambropoulou M, Papatsoris AG, Zachos I, Konstantinopoulos PA.

Sarcoma. 2008;2008:458709. doi: 10.1155/2008/458709. Epub 2008 Nov 18.

45.

Educational and social-ethical issues in the pursuit of molecular medicine.

Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG.

Mol Med. 2009 Jan-Feb;15(1-2):60-3. doi: 10.2119/molmed.2008.00120. Epub 2008 Dec 10. Review.

46.

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS).

Kalofonos HP, Kourousis C, Karamouzis MV, Iconomou G, Tsiata E, Tzorzidis F, Megas P, Lambiris E, Georgoulias V.

Sarcoma. 2004;8(4):129-33. doi: 10.1080/13577140400016705.

47.

Head and neck cancer.

Argiris A, Karamouzis MV, Raben D, Ferris RL.

Lancet. 2008 May 17;371(9625):1695-709. doi: 10.1016/S0140-6736(08)60728-X. Review.

PMID:
18486742
48.

Effect of aspirin use on thiazolidinediones and cardiovascular events.

Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG.

JAMA. 2008 Apr 2;299(13):1539; author reply 1539-40. doi: 10.1001/jama.299.13.1539-a. No abstract available.

PMID:
18387925
49.

ErbB/HER receptor family in breast cancer--the more we search the more we learn.

Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG.

Ann Oncol. 2008 May;19(5):1020-1. doi: 10.1093/annonc/mdn061. Epub 2008 Mar 19. No abstract available.

PMID:
18356136
50.

Matrix metalloproteinase inhibitors as anticancer agents.

Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG.

Int J Biochem Cell Biol. 2008;40(6-7):1156-68. doi: 10.1016/j.biocel.2007.11.007. Epub 2007 Nov 22. Review.

PMID:
18164645

Supplemental Content

Loading ...
Support Center